Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension

Omapatrilat represents a new class of drugs capable of inhibiting both ACE and neutral endopeptidase 24.11, the so-called vasopeptidase inhibitors. It therefore contributes to neurohumoral modulation, which might improve endothelial function in cardiovascular diseases. This study investigated the ef...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 2001-04, Vol.37 (4), p.1108-1113
Main Authors: QUASCHNING, Thomas, D'USCIO, Livius V, SHAW, Sidney, LÜSCHER, Thomas F
Format: Article
Language:English
Subjects:
Analysis of Variance
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Animals
Antihypertensive agents
Aorta - drug effects
Biological and medical sciences
Blood Pressure - drug effects
Captopril - therapeutic use
Cardiovascular system
Endothelin-1 - metabolism
Endothelium, Vascular - drug effects
Enzyme Inhibitors - therapeutic use
Hypertension - drug therapy
Hypertension - etiology
Hypertension - metabolism
Hypertension - physiopathology
Male
Medical sciences
Neprilysin - antagonists & inhibitors
Nitrates - metabolism
Nitric Oxide Synthase - metabolism
Nitrites - metabolism
Pharmacology. Drug treatments
Pyridines - therapeutic use
Regression Analysis
Renal Artery - drug effects
Sodium, Dietary
Statistics, Nonparametric
Thiazepines - therapeutic use
Vasoconstriction - drug effects
Vasodilation - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Omapatrilat represents a new class of drugs capable of inhibiting both ACE and neutral endopeptidase 24.11, the so-called vasopeptidase inhibitors. It therefore contributes to neurohumoral modulation, which might improve endothelial function in cardiovascular diseases. This study investigated the effect of omapatrilat in comparison to the ACE inhibitor captopril on systolic blood pressure and endothelial function in salt-induced hypertension. Dahl salt-sensitive rats (n=6/group) on standard or salt-enriched (4% NaCl) chow were treated for 8 weeks with either omapatrilat (36+/-4 mg/kg per day), captopril (94+/-2 mg/kg per day), or placebo. Aortic rings were then isolated and suspended in organ chambers for isometric tension recording. Systolic blood pressure of salt-fed, placebo-treated animals increased to 196+/-6 mm Hg, which was prevented by omapatrilat (162+/-5 mm Hg, P
ISSN:0194-911X
1524-4563
DOI:10.1161/01.HYP.37.4.1108